These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23353592)

  • 1. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.
    Weiss J; Theile D; Rüppell MA; Speck T; Spalwisz A; Haefeli WE
    Eur J Pharmacol; 2013 Feb; 701(1-3):168-75. PubMed ID: 23353592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
    Weiss J; Haefeli WE
    Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
    Weiss J; Haefeli WE
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.
    Weiss J; Baumann S; Theile D; Haefeli WE
    Pulm Pharmacol Ther; 2015 Feb; 30():80-6. PubMed ID: 25535031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
    Weiss J; Becker JP; Haefeli WE
    Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
    Rickert V; Haefeli WE; Weiss J
    Pulm Pharmacol Ther; 2014 Aug; 28(2):130-7. PubMed ID: 24657506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern.
    Treiber A; Delahaye S; Seeland S; Gnerre C
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00619. PubMed ID: 32613761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.
    Weiss J; Herzog M; Haefeli WE
    Eur J Pharmacol; 2011 Jun; 660(2-3):298-304. PubMed ID: 21501604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macitentan does not interfere with hepatic bile salt transport.
    Treiber A; Äänismaa P; de Kanter R; Delahaye S; Treher M; Hess P; Sidharta P
    J Pharmacol Exp Ther; 2014 Jul; 350(1):130-43. PubMed ID: 24769543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
    Weiss J; Theile D; Spalwisz A; Burhenne J; Riedel KD; Haefeli WE
    Biochem Pharmacol; 2013 Jan; 85(2):265-73. PubMed ID: 23219525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
    Gatfield J; Mueller Grandjean C; Bur D; Bolli MH; Nayler O
    PLoS One; 2014; 9(9):e107809. PubMed ID: 25226600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.
    Doricakova A; Theile D; Weiss J; Vrzal R
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):49-59. PubMed ID: 27678410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
    Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA; Soeding PF; Hughes RJA; Wright CE
    Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
    Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
    Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
    Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
    Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.
    Weiss J; Theile D; Dvorak Z; Haefeli WE
    Pharmaceutics; 2014 Dec; 6(4):632-50. PubMed ID: 25521244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.